Insmed

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

At Insmed, we are driven to develop medicines that can make a meaningful difference in the lives of people with rare lung diseases. We strive to create safe, effective, and affordable therapies that meet the unique needs of patients, physicians, and caregivers.

Our vision is for all patients with rare lung diseases to access the medicines they need and to lead productive, fulfilling lives.

In 2014, Insmed received the 2014 Corporate Culture Award from SmartCEO Magazine, and in 2016, the Company was named to Forbes’ list of “50 Most Innovative Pharmaceutical and Biotech Companies”.